Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

RBCC Scouts New Biotech Innovations at NIBA Investment Conference



  RBCC Scouts New Biotech Innovations at NIBA Investment Conference

NIBA Investment Conference 2012

Business Wire

NOKOMIS, Fla. -- November 14, 2012

Rainbow Coral Corp. (OTCBB: RBCC) executives will be on hand this week at the
124^th National Investment Banking Association (NIBA) Investment Conference in
Las Vegas to seek out new partnership opportunities in the red-hot
biotechnology sector.

The conference offers a chance for public and private companies to make formal
presentations to corporations such as RBCC biotech subsidiary Rainbow
Biosciences that are interested in new innovations ripe for capital
investment.

“We’re particularly interested in discovering additional projects that exhibit
short paths to marketability,” said RBCC CEO Patrick Brown. “We look forward
to networking with hungry entrepreneurs and emerging businesses with the
potential to grow our base of assets and increase shareholder value.”

RBCC is already hard at work helping to bring incredible new healthcare
technologies to new markets. The company’s joint venture partner, Nano3D
BioSciences (n3D) has developed a revolutionary 3D cell-culturing system that
could soon lead to a breakthrough in cancer research. RBCC has also finalized
joint venture terms with Amarantus BioSciences (OTCBB: AMBS), makers of a
ground-breaking new blood-test diagnostic for Parkinson’s disease.

The company hopes to add to its portfolio of projects for commercialization at
this week’s NIBA conference.

Rainbow BioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories
(NYSE: ABT).

For more information on Rainbow BioSciences, please visit
www.rainbowbiosciences.com/investors.

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The
company continually seeks out new partnerships with biotechnology developers
to deliver profitable new medical technologies and innovations. For more
information on our growth-oriented business initiatives, please visit our
website at www.rainbowbiosciences.com. For investment information and
performance data on the company, please
visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement